查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864270

酒精使用障碍市场按药物类别、治疗类型、最终用户、通路和剂型划分－2025-2032年全球预测

Alcohol Use Disorder Market by Drug Class, Treatment Type, End User, Distribution Channel, Formulation - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，酒精使用障碍市场将成长至 21.7 亿美元，复合年增长率为 6.76%。

关键市场统计数据
基准年 2024 12.8亿美元
预计年份：2025年 13.7亿美元
预测年份 2032 21.7亿美元
复合年增长率 (%) 6.76%

透过整合式照护路径、持续药物治疗和数位化服务模式，了解不断变化的酒精使用障碍治疗格局，从而为策略决策提供基础。

随着临床实践、药物选择和治疗模式的融合，酒精使用障碍 (AUD) 的治疗模式正在迅速发展，以充分满足日益增长的实证治疗需求。长效製剂和多模式疗法的进步重塑了治疗概念，而数位平台和远端医疗则拓宽了就医途径。因此，AUD 管理体系如今更加强调持续復健、个人化治疗组合以及在各种医疗环境中持续参与的策略。

应对治疗方法、数位化途径、支付方奖励和消除污名化等方面的多方面变革，以重塑酒精使用障碍 (AUD) 的治疗服务。

一系列变革正在重塑整个医疗保健系统中酒精使用障碍（AUD）的识别、治疗和管理方式。首先，治疗方法创新正从传统的口服药物扩展到包括注射长效药物，这些药物能够提高患者依从性并降低復发风险，促使临床医生重新思考治疗方法的启动和维持策略。伴随这种多样化而来的是，人们更加重视多学科方法，将行为疗法和药物疗法结合，以增强短期疗效和长期康復效果。

分析2025年关税变化对酒精使用障碍药物供应链区域化、采购调整及生产韧性的影响

2025年美国关税调整引发了药品采购、供应链成本和製造商筹资策略的新趋势，并对酒精使用障碍相关产品和通路产生了累积影响。关税相关的成本压力迫使製造商重新评估製造地和供应商合同，推动了本地化采购和替代原材料供应商的转变。这些调整影响了口服片剂、发泡製剂和注射剂的前置作业时间和库存管理，导致製造商更加依赖缓衝库存并寻求物流合作伙伴的多元化。

提取与营运相关的细分洞察，涵盖药物类别、治疗方法、临床环境、通路和製剂策略，以指导商业化和临床应用。

细緻的市场区隔分析揭示了不同药物类别、治疗方法、医疗机构、通路和剂型所面临的独特机会和关键执行挑战。依药物类别划分，市场包括Acamprosate、Disulfiram和纳曲酮。Acamprosate发泡泡腾片和口服片剂可支持不同的依从性和耐受性。Disulfiram主要以口服片剂形式使用，强调监督给药和行为指导。纳曲酮既有註射剂也有口服片剂，使临床医生能够根据患者的依从性风险和合併症情况制定个人化的起始治疗策略。这些差异指南临床定位和通讯，强调起效时间、依从机制和相对耐受性。

区域比较分析突显了美洲、欧洲、中东和非洲以及亚太地区的支付方复杂性、监管多样性和数位化准入趋势。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的治疗可近性、监管方式和服务提供模式产生了重大影响。在美洲，整合的医疗保健系统和不断扩展的远端医疗基础设施促进了联合治疗模式和长效注射剂的快速普及。同时，多元化的支付方格局要求灵活的报销策略和稳健的卫生经济学，以确保新型疗法被纳入处方笺目录并获得治疗方法覆盖。此外，该地区的跨境供应链会根据不断变化的关税和物流情况动态调整，从而推动区域采购的调整。

检验了企业如何透过结合多元化的产品系列、分销管道伙伴关係、真实世界数据 (RWE) 生成和供应链韧性等策略，来加速治疗方案的推广应用并确保可持续的药物取得。

主要企业层面的发展趋势集中在产品组合多元化、通路伙伴关係以及对患者支援基础设施的投资。领先的製造商和专业分销商正优先考虑整合商业模式，将产品供应与依从性计划、数位监测工具和临床医生教育相结合，以推动产品应用并优化治疗效果。製药公司与专业药房和远端医疗提供者之间的策略联盟正在简化长效疗法的应用流程，并支持患者从住院过渡到门诊治疗期间的护理连续性。

调整支付方伙伴关係，以永续改善医疗服务获取，优先考虑供应链韧性、整合药物和行为计划以及数位化医疗服务。

产业领导者应采取双管齐下的策略，将战术性营运韧性与长期的临床和商业性定位相结合。短期内，企业应优先考虑供应链多元化，实施双重采购和区域生产，以降低关税相关中断带来的风险，并确保口服、发泡和注射产品的稳定供应。同时，与医院药局、专科药局和零售合作伙伴协调采购和库存策略，将确保在急诊和维持治疗环境中的供应稳定性。

本研究采用混合方法证据综合分析，结合关键相关人员访谈、临床文献、监管趋势和情境建模，以确保研究结果的严谨性和可操作性。

本研究途径采用混合研究方法，将质性一手研究与同侪审查文献、临床指引、监理通讯和已发布的政策声明等二手资料综合分析结合。一手数据包括对住院和门诊临床医生、医院和专科药房的采购人员以及生产商和经销商的高管进行的结构化访谈。这些访谈提供了关于产品推广驱动因素、管理障碍以及製剂和通路选择对营运影响的实地观点。

整合治疗方法创新、不断发展的给药方式和运作韧性之间的相互作用，以确定永续临床和商业性影响的优先事项。

治疗方法、服务途径和政策方面的融合趋势，正为酒精使用障碍照护领域的相关人员创造一个关键时刻。製剂技术的创新和综合治疗方法的进步，拓展了临床医生可用的工具箱；而数位化平台和不断演进的报销模式，则为维持患者参与度和展现价值开闢了新的途径。供应炼和关税压力凸显了营运韧性的重要性，同时也奖励对区域能力和采购多元化进行策略性投资，从而实现长期稳定。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过将数位疗法和远端医疗解决方案整合到实证酒精使用障碍治疗中，改善患者疗效
  • 人工智慧驱动的预测分析在行动医疗应用中的日益普及，正在推动个人化酒精渴求管理和復发预防。
  • 长效注射用纳曲酮和其他先进的缓释性药物的出现，提高了酒精使用障碍治疗的依从性。
  • 远距精神病学平台快速发展，为酒精使用障碍患者提供远端咨询和药物管理。
  • 利用遗传和神经生物学标记开发精准医疗策略，以实现酒精使用障碍的个人化药物治疗。
  • 认知行为咨商和虚拟实境暴露疗法正日益融合，以更有效地解决酒精使用障碍的诱因。
  • 扩大由雇主主导的数位介入计画规模，这些计画将远端监测和同侪支持纳入酒精使用障碍復健治疗中。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的酒精使用疾患市场

  • Acamprosate
    • 发泡
    • 口服锭剂
  • Disulfiram
    • 口服锭剂
  • 纳曲酮
    • 注射
    • 口服锭剂

9. 依治疗类型分類的酒精使用疾患市场

  • 行为疗法
    • 认知行为疗法
    • 家庭治疗
    • 动机增强疗法
  • 联合疗法
    • 药物辅助认知行为疗法
    • 药物辅助的动机增强疗法
  • 药物治疗
    • 注射药物
    • 口服药物

10. 按最终用户分類的酒精使用障碍市场

  • 居家医疗
    • 家庭到府医疗服务
    • 远端医疗
  • 医院
    • 私立医院
    • 公立医院
  • 復健中心
    • 住院病人
    • 门诊
  • 专科诊所
    • 酒精成瘾康復诊所
    • 精神病诊所

11. 按分销管道分類的酒精使用障碍市场

  • 医院药房
    • 私立医院药房
    • 公立医院药房
  • 网路药房
    • 电子商务网站
    • 行动应用
  • 零售药房
    • 连锁药局
    • 独立药房
  • 专科药房
    • 酒精使用障碍（AUD）专科药房
    • 普通药房和专科药房

12. 依配方分類的酒精使用障碍市场

  • 分散片
  • 发泡
  • 注射
    • 肌肉内注射
    • 静脉注射
    • 皮下注射
  • 口服锭剂
    • 立即生效
    • 缓释性

13. 各地区酒精使用疾患市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 按群体分類的酒精使用障碍市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国酒精使用疾患市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Alkermes plc
    • H. Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma Ltd.
    • Lupin Limited
    • Cipla Limited
Product Code: MRR-351BAD503A27

The Alcohol Use Disorder Market is projected to grow by USD 2.17 billion at a CAGR of 6.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.28 billion
Estimated Year [2025] USD 1.37 billion
Forecast Year [2032] USD 2.17 billion
CAGR (%) 6.76%

Framing the evolving Alcohol Use Disorder treatment landscape with integrated care pathways, long-acting pharmacotherapies, and digital access models to inform strategic decisions

The landscape of Alcohol Use Disorder (AUD) care is rapidly evolving as clinical practice, pharmacologic options, and delivery models converge to better meet the growing demand for evidence-based treatment. Advances in long-acting formulations and multimodal approaches have reframed treatment conversations, while digital platforms and telehealth have expanded pathways to care. Consequently, the continuum of AUD management now emphasizes sustained recovery, individualized therapeutic combinations, and durable engagement strategies across diverse care settings.

Clinicians and health system leaders are increasingly prioritizing integrated care pathways that combine behavioral interventions with pharmacotherapy, and payers are recalibrating coverage criteria in response to outcomes data and cost-of-care considerations. Meanwhile, regulatory movements and public health campaigns are shaping perceptions and access, underscoring the importance of adaptable clinical protocols and supply-chain resilience. This introduction outlines the main forces reshaping treatment paradigms, highlights the intersection of technology and therapeutics, and situates stakeholders to capitalize on actionable insights emerging across clinical, regulatory, and commercial domains.

Navigating multipronged changes in therapy modalities, digital access pathways, payer incentives, and stigma reduction that are reshaping Alcohol Use Disorder care delivery

A series of transformative shifts is redefining how AUD is identified, treated, and managed across healthcare systems. First, therapeutic innovation has expanded beyond traditional oral dosing to include injectable long-acting agents that improve adherence and reduce relapse risk, prompting clinicians to reconsider initiation and maintenance strategies. This therapeutic diversification is accompanied by renewed emphasis on combination approaches that align behavioral therapies with pharmacotherapies to bolster both short-term engagement and long-term recovery trajectories.

Concurrently, digital health solutions are changing patient touchpoints. Telehealth and remote monitoring enable continuity of care for patients in rural or underserved areas and facilitate stepped-care models that move patients between intensity levels according to real-time clinical signals. These digital pathways also create opportunities for novel adherence interventions and remote behavioral coaching that complement in-person services. Meanwhile, payer and regulatory environments are responding to these innovations with more nuanced coverage determinations and value-based contracting pilots that prioritize measurable outcomes over service volume.

Finally, public and provider awareness campaigns have shifted stigma-related barriers to care, increasing screening rates and early intervention. Collectively, these changes generate a more patient-centric, outcomes-oriented ecosystem that rewards integrated care, device-enabled adherence, and evidence-based combinations of behavioral and pharmacologic modalities. Stakeholders who align product development, distribution, and clinical training with these shifts are positioned to lead in both clinical impact and commercial performance.

Analyzing how 2025 tariff shifts catalyzed supply chain regionalization, procurement adaptations, and manufacturing resilience for Alcohol Use Disorder therapies

United States tariff adjustments in 2025 introduced new dynamics into pharmaceutical procurement, supply chain costs, and manufacturer sourcing strategies, with cumulative consequences for AUD-related products and distribution channels. Tariff-related cost pressures compelled manufacturers to reassess manufacturing footprints and supplier contracts, prompting shifts toward regionalized sourcing and alternative raw material suppliers. These adjustments influenced lead times and inventory practices for oral tablets, effervescent formulations, and injectable therapeutics, encouraging greater reliance on buffer inventories and diversified logistics partners.

In turn, hospital pharmacies, specialty pharmacies, and retail distributors adjusted procurement cadence to mitigate exposure to pricing volatility. Some providers increased contract durations with preferred suppliers to lock in price stability, while others explored consignment and group-purchasing arrangements to preserve access without disproportionately transferring costs to patients. These procurement adaptations affected the availability of both immediate-release and sustained-release oral formulations as well as injectable intramuscular and subcutaneous options, with downstream implications for initiation protocols and adherence programs.

Additionally, the tariff environment accelerated conversations around domestic manufacturing incentives and reshored capacity for critical excipients and finished-dose forms. Policymakers and industry leaders engaged in dialogue about incentives to stabilize supply chains and reduce systemic vulnerability. As a result, strategic planning for commercialization now routinely incorporates tariff scenario modeling, dual-sourcing strategies, and cost-pass-through considerations to maintain therapeutic continuity for patients while preserving financial viability for manufacturers and distributors.

Distilling operationally relevant segmentation insights across drug classes, treatment modalities, care settings, distribution channels, and formulation strategies to guide commercialization and clinical adoption

A nuanced segmentation analysis reveals distinct opportunities and execution imperatives across drug classes, treatment modalities, care settings, distribution channels, and formulation types. Within drug classes, the market includes acamprosate, disulfiram, and naltrexone; acamprosate's effervescent and oral tablet presentations support different adherence and tolerability profiles, disulfiram is primarily deployed in oral tablet form where supervised administration and behavioral frameworks are emphasized, and naltrexone is available both as injectables and oral tablets, enabling clinicians to tailor initiation strategies based on patient adherence risk and comorbidity profiles. These distinctions inform clinical positioning and messaging that emphasize onset of effect, adherence mechanisms, and comparative tolerability.

When examining treatment types, behavioral therapy, combined therapy, and pharmacotherapy create complementary pathways for intervention. Behavioral therapy encompasses cognitive behavioral therapy, family therapy, and motivational enhancement therapy, each addressing different psychosocial drivers of substance use and recovery readiness. Combined therapy-such as cognitive behavioral therapy with pharmacotherapy or motivational enhancement therapy with pharmacotherapy-integrates pharmacologic support with structured psychosocial interventions to enhance engagement and outcomes. Pharmacotherapy itself bifurcates into injectable and oral drugs, which present divergent needs in terms of dispensing, monitoring, and reimbursement practices. Understanding the interplay between these treatment paradigms is critical for designing integrated care protocols and training programs for multidisciplinary teams.

End-user segmentation further differentiates operational requirements and access patterns. Home healthcare, hospitals, rehabilitation centers, and specialty clinics each demand tailored service models. Home healthcare services leverage home visits and telehealth to extend continuity for patients who prefer community-based care, hospitals-both private and public-serve as high-acuity initiation points where inpatient stabilization and transitioning to outpatient care are coordinated, rehabilitation centers operate across inpatient and outpatient modalities to support structured recovery programs, and specialty clinics, including alcohol rehabilitation and psychiatric clinics, focus on longitudinal follow-up and complex case management. These distinctions affect referral pathways, reimbursement mechanisms, staffing models, and the design of adherence support services.

Distribution channel segmentation highlights the importance of channel-specific strategies. Hospital pharmacies-split between private and public institutions-must balance formulary access and acute-care needs, online pharmacies accessed via e-commerce websites and mobile apps facilitate convenience and discreet delivery for maintenance therapy, retail pharmacies comprised of chain and independent outlets provide widespread dispensing capability and patient counseling touchpoints, and specialty pharmacies, both addiction-focused and general, offer medication therapy management and care coordination for complex cases. Tailoring supply chain logistics, patient education, and specialty services to these channels enhances access and retention.

Finally, formulation segmentation-dispersible tablet, effervescent tablet, injectable, and oral tablet-demands careful commercialization choices. Injectable forms include intramuscular, intravenous, and subcutaneous routes that vary in administration setting and clinical workflow, while oral tablets encompass immediate-release and sustained-release profiles that influence dosing frequency and adherence support needs. Bringing these formulation insights together enables manufacturers, payers, and providers to align product development, reimbursement strategies, and patient support programs with real-world clinical utilization patterns and operational constraints.

Comparative regional dynamics revealing payer complexity, regulatory heterogeneity, and digital-enabled access trajectories across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence treatment access, regulatory approaches, and service delivery models across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and expanding telehealth infrastructure have supported rapid adoption of combined therapy models and long-acting injectables, while diverse payer landscapes necessitate flexible reimbursement strategies and robust health economics narratives to secure formulary placement and coverage for newer modalities. Cross-border supply chains in the region also respond dynamically to tariff and logistics changes, prompting localized procurement adjustments.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and variable health system capacities create both challenges and targeted opportunities. High-income markets within this region often lead with structured national treatment guidelines and strong specialty clinic networks, supporting adoption of evidence-backed combination treatments and specialty pharmacy services. Conversely, lower-resource settings emphasize task-shifting, community-based interventions, and scalable behavioral programs, which present opportunities to leverage telehealth and simplified pharmacotherapy regimens that are easy to deploy at scale.

The Asia-Pacific region exhibits a mix of rapid urbanization, growing healthcare infrastructure investment, and distinct cultural attitudes toward substance use that shape demand and care pathways. Increasing investments in specialty clinics, expanding private hospital networks, and mobile health penetration create fertile ground for novel distribution channels such as mobile app-enabled pharmacy services and hybrid home healthcare models. Across regions, supply-chain resilience, regulatory alignment, and culturally tailored patient engagement approaches emerge as cross-cutting enablers for successful deployment of AUD therapeutics and integrated care services.

Examining company strategies that combine diversified portfolios, channel partnerships, real-world evidence generation, and supply-chain resilience to drive uptake and sustain access

Key company-level dynamics center on portfolio diversification, channel partnerships, and investments in patient support infrastructure. Leading manufacturers and specialty distributors increasingly prioritize integrated commercial models that pair product availability with adherence programs, digital monitoring tools, and clinician education to accelerate uptake and optimize outcomes. Strategic partnerships between pharmaceutical firms and specialty pharmacies or telehealth providers enable streamlined initiation processes for long-acting therapies and support continuity of care across inpatient and outpatient transitions.

Additionally, contract strategies and value-based arrangements are gaining prominence as payers seek measurable outcome improvements and cost containment. Companies that can demonstrate robust real-world evidence and offer bundled services-such as medication management, tele-coaching, and outcome tracking-are better positioned to negotiate favorable coverage terms. Supply-chain investments, including dual-sourcing, regional manufacturing partnerships, and contingency inventories, have become integral to preserving product availability and mitigating tariff-related disruptions.

Finally, companies that invest in clinician training, stigma-reduction campaigns, and culturally sensitive patient materials tend to secure stronger prescriber relationships and higher initiation rates. By aligning commercial efforts with evidence-based clinical practices and responsive distribution strategies, market participants can drive both clinical impact and sustainable business performance in a complex and rapidly evolving therapeutic area.

Prioritize supply-chain resilience, integrated pharmacotherapy and behavioral programs, and digital-enabled care while aligning payer partnerships for durable access gains

Industry leaders should adopt a dual-focus strategy that combines tactical operational resilience with long-term clinical and commercial positioning. In the near term, firms must prioritize supply-chain diversification, implementing dual-sourcing and regional manufacturing arrangements to reduce exposure to tariff-driven disruptions and ensure consistent access to oral, effervescent, and injectable formulations. At the same time, aligning procurement and inventory strategies with hospital pharmacies, specialty pharmacies, and retail partners will safeguard availability across both acute and maintenance settings.

Concurrently, organizations should invest in integrated care enablement by scaling programs that combine pharmacotherapy with evidence-based behavioral therapies. Embedding cognitive behavioral therapy, family therapy, and motivational enhancement therapy into care pathways alongside pharmacologic options encourages adherence and supports sustained recovery. Companies can accelerate adoption by funding clinician education, supporting multidisciplinary care teams, and offering reimbursement-ready value propositions grounded in real-world outcomes.

To capture long-term value, leaders must also prioritize digital engagement and home-based care models. Telehealth, mobile adherence tools, and remote monitoring expand reach and reduce barriers to care, especially when paired with specialty pharmacy support and telepharmacy services. Finally, fostering payer partnerships through transparent outcomes measurement and pilot value-based agreements will facilitate broader access; by demonstrating measurable improvements in clinical and economic endpoints, organizations can de-risk coverage decisions and create a favorable environment for innovative therapies and service bundles.

Employing a mixed-methods evidence synthesis that triangulates primary stakeholder interviews, clinical literature, regulatory signals, and scenario modeling to ensure actionable rigor

The research approach combined a mixed-methods design that integrated primary qualitative engagement with secondary synthesis of peer-reviewed literature, clinical guidelines, regulatory communications, and publicly available policy statements. Primary inputs included structured interviews with clinicians across inpatient and outpatient settings, procurement leaders at hospital and specialty pharmacies, and executives from manufacturers and distributors. These engagements provided frontline perspectives on adoption drivers, administrative barriers, and the operational implications of formulation and channel choices.

Secondary analysis synthesized clinical trial literature, guideline updates, and health system policy changes to contextualize primary insights and validate observed trends. The methodology emphasized triangulation: qualitative findings were cross-referenced with published clinical evidence and regulatory developments to strengthen analytic rigor. Scenario analysis simulated the operational impacts of supply-chain disruptions and tariff shifts, while thematic coding of interview transcripts identified recurring barriers and enablers related to initiation, adherence, and reimbursement.

Throughout, emphasis was placed on transparency and reproducibility. Data sources were documented, stakeholder selection criteria were specified to ensure representativeness across care settings and regions, and analytic steps were recorded to permit replication. This methodology supports defensible conclusions and actionable recommendations while reflecting the multifaceted realities of clinical practice, procurement, and commercialization in AUD care.

Synthesize the interplay between therapeutic innovation, delivery evolution, and operational resilience to define priorities for sustainable clinical and commercial impact

The converging trends in therapeutics, delivery channels, and policy create a decisive moment for stakeholders involved in Alcohol Use Disorder care. Innovations in formulation and integrated treatment approaches are expanding the toolkit available to clinicians, while digital platforms and evolving reimbursement paradigms create new pathways to sustain engagement and demonstrate value. Supply-chain and tariff pressures underscore the importance of operational resilience, yet they also incentivize strategic investments in regional capacity and diversified sourcing that can yield long-term stability.

In summary, success will hinge on coordinated action across product development, distribution, clinical training, and payer engagement. Stakeholders who proactively design integrated care models, invest in adherence-enabling technologies, and cultivate payer relationships anchored in real-world outcomes will be best positioned to improve patient trajectories and secure sustainable commercial performance. The pathway forward requires balanced attention to immediate operational risks and long-term clinical and economic value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of digital therapeutics and telehealth solutions in evidence-based alcohol use disorder treatment to improve patient outcomes
  • 5.2. Rising adoption of AI-driven predictive analytics in mobile health apps to personalize alcohol craving management and relapse prevention
  • 5.3. Emergence of long-acting injectable naltrexone and other advanced extended-release medications to enhance adherence in alcohol use disorder therapy
  • 5.4. Rapid growth of telepsychiatry platforms enabling remote counseling and medication management for individuals with alcohol use disorder
  • 5.5. Development of precision medicine strategies leveraging genetic and neurobiological biomarkers to tailor pharmacotherapy in alcohol use disorder
  • 5.6. Increasing integration of virtual reality exposure therapy with cognitive behavioral counseling to address alcohol use disorder triggers more effectively
  • 5.7. Expansion of employer-sponsored digital intervention programs incorporating remote monitoring and peer support for alcohol use disorder recovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alcohol Use Disorder Market, by Drug Class

  • 8.1. Acamprosate
    • 8.1.1. Effervescent Tablet
    • 8.1.2. Oral Tablet
  • 8.2. Disulfiram
    • 8.2.1. Oral Tablet
  • 8.3. Naltrexone
    • 8.3.1. Injectable
    • 8.3.2. Oral Tablet

9. Alcohol Use Disorder Market, by Treatment Type

  • 9.1. Behavioral Therapy
    • 9.1.1. Cognitive Behavioral Therapy
    • 9.1.2. Family Therapy
    • 9.1.3. Motivational Enhancement Therapy
  • 9.2. Combined Therapy
    • 9.2.1. Cbt With Pharmacotherapy
    • 9.2.2. Met With Pharmacotherapy
  • 9.3. Pharmacotherapy
    • 9.3.1. Injectable Drugs
    • 9.3.2. Oral Drugs

10. Alcohol Use Disorder Market, by End User

  • 10.1. Home Healthcare
    • 10.1.1. Home Visits
    • 10.1.2. Telehealth
  • 10.2. Hospitals
    • 10.2.1. Private Hospitals
    • 10.2.2. Public Hospitals
  • 10.3. Rehabilitation Centers
    • 10.3.1. Inpatient
    • 10.3.2. Outpatient
  • 10.4. Specialty Clinics
    • 10.4.1. Alcohol Rehabilitation Clinics
    • 10.4.2. Psychiatric Clinics

11. Alcohol Use Disorder Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Private Hospital Pharmacies
    • 11.1.2. Public Hospital Pharmacies
  • 11.2. Online Pharmacies
    • 11.2.1. E-Commerce Websites
    • 11.2.2. Mobile Apps
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies
  • 11.4. Specialty Pharmacies
    • 11.4.1. Aud Specialty Pharmacies
    • 11.4.2. General Specialty Pharmacies

12. Alcohol Use Disorder Market, by Formulation

  • 12.1. Dispersible Tablet
  • 12.2. Effervescent Tablet
  • 12.3. Injectable
    • 12.3.1. Intramuscular
    • 12.3.2. Intravenous
    • 12.3.3. Subcutaneous
  • 12.4. Oral Tablet
    • 12.4.1. Immediate Release
    • 12.4.2. Sustained Release

13. Alcohol Use Disorder Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Alcohol Use Disorder Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Alcohol Use Disorder Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alkermes plc
    • 16.3.2. H. Lundbeck A/S
    • 16.3.3. Teva Pharmaceutical Industries Ltd.
    • 16.3.4. Viatris Inc.
    • 16.3.5. Sandoz International GmbH
    • 16.3.6. Dr. Reddy's Laboratories Ltd.
    • 16.3.7. Sun Pharmaceutical Industries Ltd.
    • 16.3.8. Aurobindo Pharma Ltd.
    • 16.3.9. Lupin Limited
    • 16.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ALCOHOL USE DISORDER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ALCOHOL USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALCOHOL USE DISORDER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL ALCOHOL USE DISORDER